<!DOCTYPE html>
<html lang="en-US" class="svg inlinesvg smil svgclippaths -webkit-">
<head>
<title>BID Equity Fund II acquires majority stake in XClinical GmbH - BID Equity</title>

<script async src="https://www.googletagmanager.com/gtag/js?id=UA-111815438-1"></script>
<script async >
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());

 gtag('config', 'UA-111815438-1', { 'anonymize_ip': true });
</script>

<script>
    var OFID = '5c614c46060476312987528b';
</script>
<script src="https://cdn.outfunnel.com/c.js"></script>

<script src="https://lftracker.leadfeeder.com/lftracker_v1_4lZPGEjXoN3gLpBk.js"></script>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8"> 
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta content="width=device-width, initial-scale=1.0, maximum-scale=5.0, user-scalable=yes" name="viewport">
<link rel="stylesheet" type="text/css" media="screen" href="https://www.bidequity.de/wp-content/themes/bidequity/style.css">

<link rel="apple-touch-icon" sizes="57x57" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-57x57.png">
<link rel="apple-touch-icon" sizes="60x60" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-60x60.png">
<link rel="apple-touch-icon" sizes="72x72" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-72x72.png">
<link rel="apple-touch-icon" sizes="76x76" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-76x76.png">
<link rel="apple-touch-icon" sizes="114x114" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-114x114.png">
<link rel="apple-touch-icon" sizes="120x120" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-120x120.png">
<link rel="apple-touch-icon" sizes="144x144" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-144x144.png">
<link rel="apple-touch-icon" sizes="152x152" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-152x152.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/apple-icon-180x180.png">
<link rel="icon" type="image/png" sizes="192x192"  href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/android-icon-192x192.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="96x96" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/favicon-96x96.png">
<link rel="icon" type="image/png" sizes="16x16" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/favicon-16x16.png">
<link rel="manifest" href="https://www.bidequity.de/wp-content/themes/bidequity/favicon/manifest.json">
<meta name="msapplication-TileColor" content="#ffffff">
<meta name="msapplication-TileImage" content="https://www.bidequity.de/wp-content/themes/bidequity/favicon/ms-icon-144x144.png">
<meta name="theme-color" content="#ffffff">

<link rel="alternate" hreflang="de" href="https://www.bidequity.de/bid-equity-fund-ii-uebernimmt-mehrheit-an-der-xclinical-gmbh/" />
<link rel="alternate" hreflang="en" href="https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en" />

	<!-- This site is optimized with the Yoast SEO plugin v15.6.2 - https://yoast.com/wordpress/plugins/seo/ -->
	<meta name="description" content="BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies. The XClinical platform fully implements the CDISC standard, which significantly accelerates the analysis and submission of data to regulatory authorities." />
	<meta name="robots" content="index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1" />
	<link rel="canonical" href="https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en" />
	<meta property="og:locale" content="en_US" />
	<meta property="og:type" content="article" />
	<meta property="og:title" content="BID Equity Fund II acquires majority stake in XClinical GmbH - BID Equity" />
	<meta property="og:description" content="BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies. The XClinical platform fully implements the CDISC standard, which significantly accelerates the analysis and submission of data to regulatory authorities." />
	<meta property="og:url" content="https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en" />
	<meta property="og:site_name" content="BID Equity" />
	<meta property="article:published_time" content="2019-09-13T07:16:03+00:00" />
	<meta property="og:image" content="https://www.bidequity.de/wp-content/uploads/header2.jpg" />
	<meta property="og:image:width" content="5400" />
	<meta property="og:image:height" content="3600" />
	<meta name="twitter:card" content="summary_large_image" />
	<meta name="twitter:label1" content="Written by">
	<meta name="twitter:data1" content="BIDEquity">
	<meta name="twitter:label2" content="Est. reading time">
	<meta name="twitter:data2" content="1 minute">
	<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"https://www.bidequity.de/?lang=en/#website","url":"https://www.bidequity.de/?lang=en/","name":"BID Equity","description":"","potentialAction":[{"@type":"SearchAction","target":"https://www.bidequity.de/?lang=en/?s={search_term_string}","query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en#primaryimage","inLanguage":"en-US","url":"https://www.bidequity.de/wp-content/uploads/header2.jpg","width":5400,"height":3600},{"@type":"WebPage","@id":"https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en#webpage","url":"https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en","name":"BID Equity Fund II acquires majority stake in XClinical GmbH - BID Equity","isPartOf":{"@id":"https://www.bidequity.de/?lang=en/#website"},"primaryImageOfPage":{"@id":"https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en#primaryimage"},"datePublished":"2019-09-13T07:16:03+00:00","dateModified":"2019-09-13T07:16:03+00:00","author":{"@id":"https://www.bidequity.de/?lang=en/#/schema/person/ef40411c722ac7709475af53ed552883"},"description":"BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies. The XClinical platform fully implements the CDISC standard, which significantly accelerates the analysis and submission of data to regulatory authorities.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en"]}]},{"@type":"Person","@id":"https://www.bidequity.de/?lang=en/#/schema/person/ef40411c722ac7709475af53ed552883","name":"BIDEquity","image":{"@type":"ImageObject","@id":"https://www.bidequity.de/?lang=en/#personlogo","inLanguage":"en-US","url":"https://secure.gravatar.com/avatar/f9ddfcc5a5a76e8e2dd9d2cca2264945?s=96&d=mm&r=g","caption":"BIDEquity"}}]}</script>
	<!-- / Yoast SEO plugin. -->


<link rel='stylesheet' id='wp-block-library-css'  href='https://www.bidequity.de/wp-includes/css/dist/block-library/style.min.css?ver=5.6' type='text/css' media='all' />
<link rel='stylesheet' id='contact-form-7-css'  href='https://www.bidequity.de/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=5.3.2' type='text/css' media='all' />
<link rel='stylesheet' id='menu-image-css'  href='https://www.bidequity.de/wp-content/plugins/menu-image/includes/css/menu-image.css?ver=3.0.4' type='text/css' media='all' />
<link rel='stylesheet' id='dashicons-css'  href='https://www.bidequity.de/wp-includes/css/dashicons.min.css?ver=5.6' type='text/css' media='all' />
<link rel='stylesheet' id='wpml-menu-item-0-css'  href='//www.bidequity.de/wp-content/plugins/sitepress-multilingual-cms/templates/language-switchers/menu-item/style.css?ver=1' type='text/css' media='all' />
<script type='text/javascript' src='https://www.bidequity.de/wp-includes/js/jquery/jquery.min.js?ver=3.5.1' id='jquery-core-js'></script>
<script type='text/javascript' src='https://www.bidequity.de/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.3.2' id='jquery-migrate-js'></script>
<link rel="https://api.w.org/" href="https://www.bidequity.de/wp-json/" /><link rel="alternate" type="application/json" href="https://www.bidequity.de/wp-json/wp/v2/posts/562" /><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://www.bidequity.de/xmlrpc.php?rsd" />
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="https://www.bidequity.de/wp-includes/wlwmanifest.xml" /> 
<meta name="generator" content="WordPress 5.6" />
<link rel='shortlink' href='https://www.bidequity.de/?p=562&#038;lang=en' />
<link rel="alternate" type="application/json+oembed" href="https://www.bidequity.de/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.bidequity.de%2Fbid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh%2F%3Flang%3Den" />
<link rel="alternate" type="text/xml+oembed" href="https://www.bidequity.de/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.bidequity.de%2Fbid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh%2F%3Flang%3Den&#038;format=xml" />
<meta name="generator" content="WPML ver:4.4.8 stt:1,3;" />
<link rel="icon" href="https://www.bidequity.de/wp-content/uploads/ms-icon-310x310.png" sizes="32x32" />
<link rel="icon" href="https://www.bidequity.de/wp-content/uploads/ms-icon-310x310.png" sizes="192x192" />
<link rel="apple-touch-icon" href="https://www.bidequity.de/wp-content/uploads/ms-icon-310x310.png" />
<meta name="msapplication-TileImage" content="https://www.bidequity.de/wp-content/uploads/ms-icon-310x310.png" />
</head>
<body>
	<script> 
		window['GoogleAnalyticsObject']='ga';
		(function(){
		
			window.ldfdr = window.ldfdr || {};
			(function(d, s, ss, fs){
			fs = d.getElementsByTagName(s)[0];
		
			function ce(src){
				var cs  = d.createElement(s);
				cs.src = src;
				setTimeout(function(){fs.parentNode.insertBefore(cs,fs)}, 1);
			}
		
			ce(ss);
			})(document, 'script', 'https://lftracker.leadfeeder.com/lftracker_v1_4lZPGEjXoN3gLpBk.js');
		})();
	</script>

	<section id="navibar">
    <div id="logo">
        <a href="https://www.bidequity.de/?lang=en" class="custom-logo-link" rel="home"><img src="https://www.bidequity.de/wp-content/uploads/logo-color.svg" class="custom-logo" alt="BID Equity Logo" /></a>    </div>

    <div class="contactinfocontainer">
        <a href="tel:+49 40 822 169 420" title="+49 40 822 169 420">
            <span>PHONE</span>
            +49 40 822 169 420        </a>
        <a href="mailto:contact@bidequity.de" title="contact@bidequity.de">
            <span>MAIL</span>
            contact@bidequity.de        </a>
    </div>

    <nav id="languageswitch">
        <div class="menu-sprachen-container"><ul id="menu-sprachen" class="menu"><li id="menu-item-wpml-ls-10-de" class="menu-item wpml-ls-slot-10 wpml-ls-item wpml-ls-item-de wpml-ls-menu-item wpml-ls-first-item menu-item-type-wpml_ls_menu_item menu-item-object-wpml_ls_menu_item menu-item-wpml-ls-10-de"><a title="DE" href="https://www.bidequity.de/bid-equity-fund-ii-uebernimmt-mehrheit-an-der-xclinical-gmbh/"><span class="wpml-ls-display">DE</span></a></li>
<li id="menu-item-wpml-ls-10-en" class="menu-item wpml-ls-slot-10 wpml-ls-item wpml-ls-item-en wpml-ls-current-language wpml-ls-menu-item wpml-ls-last-item menu-item-type-wpml_ls_menu_item menu-item-object-wpml_ls_menu_item menu-item-wpml-ls-10-en"><a title="EN" href="https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-xclinical-gmbh/?lang=en"><span class="wpml-ls-display">EN</span></a></li>
</ul></div>    </nav>

    <button id="showMenu">
        <div class="container">
            <span class="menutoggle-part menutoggle-top"></span>
            <span class="menutoggle-part menutoggle-middle"></span>
            <span class="menutoggle-part menutoggle-bottom"></span>
        </div>
    </button>
</section>

	
	<div id="perspective" class="perspective effect-moveleft">
	<div class="container">
	<div class="wrapper">
	<header id="pageheader" class="section">		
		
									
									<div class="page-thumbnail">
						<div class="image interchange" data-interchange="[https://www.bidequity.de/wp-content/uploads/header2-2000x1000.jpg, mobilePortrait], [https://www.bidequity.de/wp-content/uploads/header2-2000x1000.jpg, mobileLandscape], [https://www.bidequity.de/wp-content/uploads/header2-3000x1500.jpg, tabletPortrait], [https://www.bidequity.de/wp-content/uploads/header2-3000x1500.jpg, tabletLandscape], [https://www.bidequity.de/wp-content/uploads/header2-1500x750.jpg, desktopNotebooks], [https://www.bidequity.de/wp-content/uploads/header2-2000x1000.jpg, desktopHD], [https://www.bidequity.de/wp-content/uploads/header2-3000x1500.jpg, desktopUHD], [https://www.bidequity.de/wp-content/uploads/header2-2000x1000.jpg, default]">
							<div class="layer nomobile"></div>
						</div>
						<div class="firstcontent headlinecontainer">
							<h1  class="blog"  >
																	Blog															</h1>
						</div>
					</div>
										</header>
<main class="section gray">
	<article class="blogentry wrap firstcontent">
        <section class="content-wrap">
            <h2>BID Equity Fund II acquires majority stake in XClinical GmbH</h2>
            <header class="info">
                <span class="date">13/September/2019</span>
                <span class="cat">
                    <a href='https://www.bidequity.de/blog/?lang=en?c=3' title='Transactions'>Transactions</a>                </span>
            </header>
            <div class="content">
                <p><a href="www.xclinical.com" target="_blank" rel="noopener noreferrer"><img loading="lazy" class="alignleft wp-image-552" src="https://www.bidequity.de/wp-content/uploads/xclinical-logo-1500x536.png" alt="" width="179" height="64" data-wp-editing="1" srcset="https://www.bidequity.de/wp-content/uploads/xclinical-logo-1500x536.png 1500w, https://www.bidequity.de/wp-content/uploads/xclinical-logo-768x274.png 768w, https://www.bidequity.de/wp-content/uploads/xclinical-logo-2000x714.png 2000w, https://www.bidequity.de/wp-content/uploads/xclinical-logo-24x9.png 24w, https://www.bidequity.de/wp-content/uploads/xclinical-logo-36x13.png 36w, https://www.bidequity.de/wp-content/uploads/xclinical-logo-48x17.png 48w" sizes="(max-width: 179px) 100vw, 179px" /></a></p>
<p>BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies. The XClinical platform fully implements the CDISC standard, which significantly accelerates the analysis and submission of data to regulatory authorities.</p>
<p>XClinical was founded in 2002 and offers its comprehensive SaaS platform &#8220;Marvin&#8221;, a tailor-made software solution for the support of clinical studies. In addition to data management, it also includes randomization, study equipment management, patient surveys, coding, and reporting. It covers the processes from study design to submission of results to audiences. XClinical is characterized by a high degree of flexibility and short response times, and optimally meets the requirements of its customers. Nearly 50 employees in Munich, Basel, Nantes, and New Jersey support the software and its customers all over the world.</p>
<p>The investment by BID Equity enables XClinical to accelerate its international expansion, expand its product portfolio, and further increase its level of professionalization. Together with the management team BID Equity will pursue a buy &amp; build approach to open up new markets and to firmly anchor XClinical in the fast-growing clinical trials market. &#8220;With XClinical we are adding another fast-growing company to our portfolio, which we will support in its development with our many years of experience in optimizing software business models,&#8221; says the BID Equity team.</p>
<p>&#8220;We have selected BID Equity because we are absolutely convinced that we can jointly succeed in implementing our Buy &amp; Build strategy in the area of eClinical Solutions Software&#8221;, Franciscus Pijpers, CEO of XClinical GmbH.</p>
                <a class="backlink" href="https://www.bidequity.de/blog/?lang=en" title="Back to overview">Back to overview</a>
            </div>
        </section>
        <aside class="sidebar-wrap">
            <section class="widget categories">
                <h3>
                    Blog / Categories                </h3>
                <ul class="category-list">
                                        <li>
                        <a class="termlink" href="https://www.bidequity.de/blog/?lang=en?c=3" title="Transactions">Transactions (11)</a>
                    </li>
                                        <li>
                        <a class="termlink" href="https://www.bidequity.de/blog/?lang=en" title="All categories">All categories</a>
                    </li>
                </ul>
            </section>

                            <section class="widget moreposts">
                    <h3>
                        More posts                    </h3>
                    
                    <ul class="post-list">
                                                                            <li class="otherpost">
                                <a href="https://www.bidequity.de/myneva-group-acquires-swing-to-further-strengthen-its-market-leading-position-in-the-social-software-sector/?lang=en" title="myneva Group acquires SWING to further strengthen...">myneva Group acquires SWING to further strengthen...</a>
                                <span class="date">18/September/2020</span>
                            </li>
                                                                            <li class="otherpost">
                                <a href="https://www.bidequity.de/bid-equity-fund-ii-announces-the-acquisition-of-crm-vendor-pisa-sales-gmbh-to-strengthen-the-recently-acquired-infopark-group/?lang=en" title="BID Equity Fund II announces the acquisition of...">BID Equity Fund II announces the acquisition of...</a>
                                <span class="date">19/August/2020</span>
                            </li>
                                                                            <li class="otherpost">
                                <a href="https://www.bidequity.de/bid-equity-fund-ii-acquires-majority-stake-in-infopark-group-creator-of-the-saas-based-content-management-system-scrivito/?lang=en" title="BID Equity Fund II acquires majority stake in...">BID Equity Fund II acquires majority stake in...</a>
                                <span class="date">07/August/2020</span>
                            </li>
                                            </ul>
                </section>
                    </aside>
    </article>
</main>

	<footer>
		

				<section id="contact" class="dark">
    <div class="contactinfo">
        <div class="address">
            <p>BID EQUITY GMBH<br />
Große Johannisstraße 7<br />
20457 Hamburg, Germany</p>
        </div>
        <table class="numbers">
            <tbody>
                <tr>
                    <td>PHONE</td>
                    <td><a href="tel:+49 40 822 169 420" title="+49 40 822 169 420">+49 40 822 169 420</a></td>
                </tr>
                <tr>
                    <td>FAX</td>
                    <td><a href="fax:+49 40 537 981 320" title="+49 40 537 981 320">+49 40 537 981 320</a></td>
                </tr>
                <tr>
                    <td>MAIL</td>
                    <td>
                        <a href="mailto:contact@bidequity.de" title="contact@bidequity.de">contact@bidequity.de</a>
                    </td>
                </tr>
            </tbody>
        </table>
    </div>
    <div class="upcontainer">
        <button id="upbutton" title="nach oben">
            <img src="https://www.bidequity.de/wp-content/themes/bidequity/images/arrow.svg" alt="nach oben">
        </button>
    </div>
    <div class="newsletter">
        <div class="formwrap">
            <span class="headline">Newsletter</span>
            <p class="text">Always stay up to date – subscribe to software news from BID Equity now.</p>
            <div>


            <!-- Begin Signup Form -->
            <script type="text/javascript">
                if (typeof jQuery == 'undefined') {
                    document.write('<scr' + 'ipt type="text/javascript" src="https://list.mailigen.com/js/jquery.js"></scr' + 'ipt>');
                }
            </script>
            <script language="javascript" type="text/javascript" src="https://list.mailigen.com/js/scripts.js"></script>
            <script language="javascript" type="text/javascript" src="https://list.mailigen.com/js/subscribe3.0.js"></script>
            <script language="javascript" type="text/javascript">
            jQuery(function(){ 
            jQuery('.MG-placeholder-1607073563759').MGsubscribe({ 
                type: 'inline'
            });
            });
            </script>

            <div class="MG-placeholder-1607073563759 newsletter-container">
                <form name="subscribe" class="subscribe" action="https://list.mailigen.com/subscribe/post" method="post" style="">
                    <input type="hidden" name="subscribe" value="true">
                    <input type="hidden" name="ln" value="en">
                    <input type="hidden" name="u" value="173807a8b715f1f645ae201f72ce83ac">
                    <input type="hidden" name="id" value="1a6d886c">

                    <div class="formfields" id="formfields">
                        <div class="ffields customformstyle">
                            <div class="bforms">
                                <div class="tr require" id="merge-0">
                                    <div class="c1">Email Address*</div>
                                    <div class="c2">
                                        <input type="text" class="text" name="merge[0]" accept="email" value="">
                                    </div>
                                    <div class="c3"></div>
                                </div>
                            </div>
                        </div>
                        <div class="button" style="text-align:left">
                            <button id="formSubmit" name="submit" type="submit">Subscribe</button><input type="image" name="submit" alt="Absenden" src="" style="display:none">
                        </div>
                        <div class="clear"></div>
                    </div>
                    
                    <div style="" class="label-rf">* Required field</div>
                        
                </form>
            </div>

            <!-- End Signup Form -->

            <p class="hinweis">Yes, I want subscribe to the BID EQUITY GMBH newsletter. You can unsubscribe here or inside the newsletter anytime.</p>
            <hr class="endline" />
        </div>
    </div>
</section>

						<nav id="footernavigation">
			<div class="menu-footermenu-container"><ul id="menu-footermenu" class="menu"><li id="menu-item-390" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-390"><a href="https://www.bidequity.de/contact/?lang=en">Contact</a></li>
<li id="menu-item-389" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-389"><a href="https://www.bidequity.de/imprint/?lang=en">Imprint</a></li>
<li id="menu-item-388" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-388"><a href="https://www.bidequity.de/privacy-policy/?lang=en">Privacy Policy</a></li>
</ul></div>			<span class="copyright">© 2021 bid equity gmbh</span>
		</nav>
	</footer>

	</div>
	</div>
	<nav class="outer-nav right vertical">
		<div class="menu-mainmenu-container"><ul id="menu-mainmenu" class="menu"><li id="menu-item-383" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-383"><a title="Home" href="https://www.bidequity.de/?lang=en">Home</a></li>
<li id="menu-item-380" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-380"><a title="About BID Equity" href="https://www.bidequity.de/about-bid-equity/?lang=en">About BID Equity</a></li>
<li id="menu-item-384" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-384"><a title="Investment Portfolio" href="https://www.bidequity.de/investment-portfolio/?lang=en">Investment Portfolio</a></li>
<li id="menu-item-382" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-382"><a title="Creating Value" href="https://www.bidequity.de/creating-value/?lang=en">Creating Value</a></li>
<li id="menu-item-387" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-387"><a title="Where we invest" href="https://www.bidequity.de/focus/?lang=en">Where we invest</a></li>
<li id="menu-item-386" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-386"><a title="Transaction Process" href="https://www.bidequity.de/process/?lang=en">Transaction Process</a></li>
<li id="menu-item-381" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-381"><a title="Blog" href="https://www.bidequity.de/blog/?lang=en">Blog</a></li>
<li id="menu-item-385" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-385"><a title="Our Team &#038; Career" href="https://www.bidequity.de/career/?lang=en">Our Team &#038; Career</a></li>
<li id="menu-item-421" class="investorlink menu-item menu-item-type-custom menu-item-object-custom menu-item-421"><a title="Investor portal" target="_blank" rel="noopener" href="https://icx.efrontcloud.com/BIDEQUITY/login.aspx">Investor Portal</a></li>
</ul></div>	</nav>
	</div>

	<nav id="mobilesticky">
		<div class="menu-mobile-kontakt-navigation-container"><ul id="menu-mobile-kontakt-navigation" class="menu"><li id="menu-item-28" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-28"><a title="contact@bidequity.de" href="mailto:contact@bidequity.de" class="menu-image-title-after menu-image-not-hovered"><img width="1" height="1" src="https://www.bidequity.de/wp-content/uploads/icon-mail.svg" class="menu-image menu-image-title-after" alt="Icon Mail" loading="lazy" /><span class="menu-image-title-after menu-image-title">contact@bidequity.de</span></a></li>
<li id="menu-item-33" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-33"><a title="+49 40 822 169 420" href="tel:+49%2040%20822%20169%20420" class="menu-image-title-after menu-image-not-hovered"><img width="1" height="1" src="https://www.bidequity.de/wp-content/uploads/icon-phone.svg" class="menu-image menu-image-title-after" alt="" loading="lazy" /><span class="menu-image-title-after menu-image-title">+49 40 822 169 420</span></a></li>
</ul></div>	</nav>

	<script src="https://www.bidequity.de/wp-content/themes/bidequity/js/modernizr.min.js"></script>
	<script src="https://www.bidequity.de/wp-content/themes/bidequity/js/classie.min.js"></script>
	<script src="https://www.bidequity.de/wp-content/themes/bidequity/js/what-input.min.js"></script>
	<script src="https://www.bidequity.de/wp-content/themes/bidequity/js/foundation.min.js"></script>
	<script src="https://www.bidequity.de/wp-content/themes/bidequity/js/custom.min.js"></script>
	<script src="https://www.bidequity.de/wp-content/themes/bidequity/js/menu.min.js"></script>
	

	<script type="text/javascript">
		var gaProperty = 'UA-111815438-1';
		var disableStr = 'ga-disable-' + gaProperty;
		if (document.cookie.indexOf(disableStr + '=true') > -1) {
		window[disableStr] = true;
		}
		function gaOptout() {
		document.cookie = disableStr + '=true; expires=Thu, 31 Dec 2099 23:59:59 UTC; path=/';
		window[disableStr] = true;
		alert('Das Tracking durch Google Analytics wurde in Ihrem Browser für diese Website deaktiviert.');
		}
	</script>

<script type='text/javascript' id='contact-form-7-js-extra'>
/* <![CDATA[ */
var wpcf7 = {"apiSettings":{"root":"https:\/\/www.bidequity.de\/wp-json\/contact-form-7\/v1","namespace":"contact-form-7\/v1"}};
/* ]]> */
</script>
<script type='text/javascript' src='https://www.bidequity.de/wp-content/plugins/contact-form-7/includes/js/scripts.js?ver=5.3.2' id='contact-form-7-js'></script>
<script type='text/javascript' src='https://www.bidequity.de/wp-content/plugins/wf-cookie-consent/js/cookiechoices.min.js?ver=5.6' id='wf-cookie-consent-cookiechoices-js'></script>
<script type='text/javascript' src='https://www.bidequity.de/wp-includes/js/wp-embed.min.js?ver=5.6' id='wp-embed-js'></script>
<script type="text/javascript">
	window._wfCookieConsentSettings = {"wf_cookietext":"Cookies help us deliver our services. By using our services, you agree to our use of cookies.","wf_dismisstext":"Accept","wf_linktext":"Learn more","wf_linkhref":"https:\/\/www.bidequity.de\/about-bid-equity\/?lang=en","wf_position":"bottom","language":"en"};
</script>
 
</body>
</html>